Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ATAI Life Sciences N.V shares valued at $198,408 were purchased by SAHIL KIRPEKAR on Jun 04 ’25. At $2.48 per share, SAHIL KIRPEKAR acquired 80,000 shares.
Also, Kirpekar Sahil sold 48,563 shares, netting a total of over 65,560 in proceeds. Following the sale of shares at $1.35 each, the insider now holds 115,636 shares.
Before that, Craig Kevin James had sold 11,563 shares from its account. In a trade valued at $15,610, the Chief Medical Officer traded ATAI Life Sciences N.V shares for $1.35 each. Upon closing the transaction, the insider’s holdings decreased to 11,563 shares, worth approximately $20839.390000000003.
As published in a research note from H.C. Wainwright on November 18, 2024, ATAI Life Sciences N.V [ATAI] has been retained to a Buy and the price target has been revised to $10. Analysts at Maxim Group upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early April. As of November 01, 2022, Loop Capital has initiated its “Buy” rating for ATAI. Earlier on November 30, 2021, Maxim Group initiated its rating. Their recommendation was “a Buy” for ATAI stock.
Analyzing ATAI Stock Performance
During the last five days, there has been a surge of approximately 6.93%. Over the course of the year, ATAI Life Sciences N.V shares have jumped approximately 85.71%. Shares of the company reached a 52-week high of $2.64 on 06/02/25 and a 52-week low of $1.15 on 04/09/25.
Support And Resistance Levels for ATAI Life Sciences N.V (ATAI)
According to the 24-hour chart, there is a support level at 2.35, which, if violated, would cause prices to drop to 2.24. In the upper region, resistance lies at 2.57. The next price resistance is at 2.68. RSI (Relative Strength Index) is 73.81 on the 14-day chart, showing overbought technical sentiment.
